NCT07237048 Minocycline in Stroke Study at Maimonides
| NCT ID | NCT07237048 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Joyce Chen |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,164 participants |
| Start Date | 2026-02-02 |
| Primary Completion | 2028-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 1,164 participants in total. It began in 2026-02-02 with a primary completion date of 2028-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older. The main questions it aims to answer are: 1. Does Minocycline improve \*National Institutes of Health Stroke Scale\* (NIHSS) scores at hospital discharge and 90 days post-stroke? 2. Does Minocycline reduce stroke-related disability, all-cause in hospital mortality (mRS -\*Modified Rankin Scale\* = 6) and at 90 days besides reducing brain bleeding complications compared to standard care? Researchers will compare patients receiving oral Minocycline plus standard care to those receiving standard care only to see if Minocycline leads to better neurological outcomes and lower mortality. Participants will: 1. Be randomly assigned by block to receive either: Minocycline 200 mg orally once daily for five days within 24 hours from symptoms onset + Standard Care, or Standard Care only 2. Undergo neurological assessments using NIHSS \*National Institutes of Health Stroke Scale\* and Modified Rankin Scale (mRS) at admission, discharge, 30 days post-stroke, 90 days post-stroke 3. Be monitored for: a) hemorrhagic transformation of ischemic strokes; b) Adverse events and mortality outcomes; c) Safety and efficacy signals through interim analyses NIHSS: \*National Institutes of Health Stroke Scale\*, which is stroke severity scale, mRS: \*Modified Rankin Scale\*, which is stroke disability scale
Eligibility Criteria
\* Inclusion criteria In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Age \>/=18 2. NIHSS 5-20 \*National Institutes of Health Stroke Scale\* 3. Acute onset neurological deficit consistent with acute ischemic stroke or on imaging consistent with acute ischemia as defined by WHO \*(World Health Organization) \* guidelines or acute onset of neurological deficits with intracerebral Hemorrhage on imaging consistent with intracerebral bleed 4. The onset of neurological symptoms less than 24 hours * Exclusion criteria An individual who meets any of the following criteria is excluded from participation in this study: 1. Clinically stroke is not suspected 2. Allergic to the Tetracycline group of medications or Intolerance to Minocycline 3. Pregnancy or suspected pregnancy or breastfeeding 4. Previous history of intolerance to Minocycline 5. Acute or chronic renal failure (stage III with GFR \*(Glomerular Filtration Rate) \* or Creatinine threshold) 6. Any patients with contraindications to undergo CT (Computed Tomography) / MRI (Magnetic Resonance Imaging) 7. Life expectancy less than one year or severe co-morbidities or comfort measure only (CMO) on admission 8. Pre-existing infectious disease requiring antibiotics 9. Inability to tolerate enteral medications/feeds 10. Patient/ family refusal
Contact & Investigator
Qingliang T. Wang, MD, PhD
PRINCIPAL INVESTIGATOR
Maimonides Medical Center
Frequently Asked Questions
Who can join the NCT07237048 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07237048 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07237048 currently recruiting?
Yes, NCT07237048 is actively recruiting participants. Contact the research team at qwang@maimo.org for enrollment information.
Where is the NCT07237048 trial being conducted?
This trial is being conducted at Brooklyn, United States.
Who is sponsoring the NCT07237048 clinical trial?
NCT07237048 is sponsored by Joyce Chen. The principal investigator is Qingliang T. Wang, MD, PhD at Maimonides Medical Center. The trial plans to enroll 1,164 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.